Murad Novruzov | Immunotherapy | Pharmaceutical Excellence Award

Published on by Top Pharmaceutical

Mr. Murad Novruzov | Immunotherapy | Pharmaceutical Excellence Award

Ronin Institute | Azerbaijan

Mr. Murad Novruzov is an independent researcher whose work spans the intersecting frontiers of immunology, cancer biology, experimental oncology, neurology, and functional neuroscience. His research focuses on building theoretical and preclinical frameworks that advance the understanding of complex diseases, particularly late-stage cancer and neurological disorders. His scientific interests include cancer immunotherapy, tumor microenvironment dynamics, bacteriotherapy, cytokine-based treatments, T-cell engineering, oncolytic bacterial systems, and enzymatic tumor disruption. Complementing his work in oncology, he also explores neuropathy rehabilitation, peripheral nerve injury mechanisms, neuroregeneration, and the development of non-surgical motor recovery protocols.Over the course of his multidisciplinary journey, Mr. Novruzov has contributed to several organizations across biomedical research, information technology, healthcare analytics, and academic innovation. He is affiliated with the Ronin Institute and serves as a researcher within Health & Science Initiatives, where he is involved in shaping novel biomedical concepts and translational research directions. His long-standing involvement in Murad Novruzov Biomedical Research reflects his commitment to independent scientific inquiry, allowing him to develop unconventional yet scientifically grounded strategies for personalized oncology and neurofunctional rehabilitation.Beyond laboratory and theoretical research, Mr. Novruzov possesses extensive experience in IT systems integration, analytical model development, and large-scale data processing. His leadership role at Minihomme highlights his ability to merge technical and scientific expertise, while his work in major healthcare institutions demonstrates his proficiency in big data analytics, clinical data interpretation, and medical informatics. His contributions extend to academia and scientific administration, where he has supported analysis system development and participated in international scientific relations at prominent institutions.Mr. Novruzov maintains a strong presence in global scientific networks through platforms such as SciProfiles and ORCID, allowing him to share his evolving body of work with the wider research community. His interdisciplinary perspective—uniting oncology, immunology, neurology, computational modeling, and IT—positions him as a versatile thinker dedicated to advancing next-generation biomedical solutions. Driven by curiosity and innovation, he continues to develop theoretical protocols aimed at transforming future approaches in personalized medicine, cancer therapy, and neuroregenerative science.

Profile: Orcid

Featured Publications

Novruzov, M., Mammadova, M., & Shiraliyeva, U. Hypothetical Mechanisms of Immune Response Activation Under Profound Suppression. Zenodo. DOI: 10.5281/ZENODO.16740757.

Novruzov, M., Mammadova, M., & Shiraliyeva, U. Hypothetical Mechanisms of Immune Response Activation Under Profound Suppression (Preprint). Preprint Server. DOI: 10.2196/preprints.86151.

Novruzov, M., Mammadova, M., Raval, K., & Shiraliyeva, U. Second Breath: Systems-Level Model of Localized Immune Cascade Programming in Desmoplastic Tumors (In Silico-Validated, Literature-Anchored) (Preprint). Preprint Server. DOI: 10.2196/preprints.85933.

Novruzov, M., Mammadova, M., Raval, K., & Shiraliyeva, U. Second Breath: Systems-Level Model of Localized Immune Cascade Programming in Desmoplastic Tumors (In Silico-Validated, Literature-Anchored) (Preprint). Preprint Server. DOI: 10.2196/preprints.85507.

Novruzov, M., Mammadova, M., Raval, K., & Shiraliyeva, U. Second Breath: Systems-Level Model of Localized Immune Cascade Programming in Desmoplastic Tumors (In Silico-Validated, Literature-Anchored). Zenodo. DOI: 10.5281/ZENODO.16736769.

Novruzov, M., & Shiraliyeva, U. Malignant Tumors: Therapeutic Modalities, Mechanisms, Step-by-Step Application, Toxicities and Clinical Interactions. Zenodo. DOI: 10.5281/ZENODO.17219649.

Qing Li | Immunotherapy | Best Researcher Award

Published on by Top Pharmaceutical

Prof. Qing Li | Immunotherapy | Best Researcher Award

Chongqing University, China

Prof. Qing Li is a distinguished researcher and academic whose pioneering contributions in molecular oncology and cancer therapeutics have significantly advanced the understanding of tumor pathogenesis and targeted treatment strategies. His extensive research focuses on elucidating the intricate signaling pathways involved in cancer progression, drug resistance, and immune evasion, with an emphasis on translating molecular insights into clinical applications. Prof. Li has co-authored and led numerous high-impact studies published in leading international journals, showcasing his commitment to bridging the gap between benchside discovery and bedside therapy.Among his major works, Prof. Li has contributed to groundbreaking research uncovering signaling pathways involved in colorectal cancer pathogenesis and targeted therapy, published in Signal Transduction and Targeted Therapy. His collaborative study in Experimental Hematology & Oncology revealed how the downregulation of pro-surfactant protein B contributes to the recurrence of early-stage non-small cell lung cancer by activating PGK1-mediated Akt signaling. In Oncogene, he provided critical insights into how hypoxia inhibits ferritinophagy-mediated ferroptosis in esophageal squamous cell carcinoma through the USP2-NCOA4 axis, while his work in Drug Resistance Updates explored spatial multi-omics approaches to circumvent drug resistance in gastric cancer, offering valuable directions for improving chemo and immuno-therapeutic responses.Prof. Li’s research also extends to nanomedicine, where he has designed innovative drug delivery systems, such as plumbagin-loaded ZIF-90 nanoparticles, to suppress gastric cancer progression by targeting the YAP1 signaling pathway, a study featured in the Chemical Engineering Journal. His investigations in Advanced Science identified the oncogenic role of SAMD9 in promoting postoperative recurrence of esophageal carcinoma via the MYH9-mediated GSK3β/β-catenin signaling cascade. Furthermore, his contributions to Seminars in Cancer Biology and Molecular Therapy have shed light on epigenetic regulation and immune checkpoint dynamics, particularly emphasizing the prognostic role of PD-L1 P146R in gastric cancer immunotherapy outcomes.Beyond publications, Prof. Qing Li has demonstrated excellence in research leadership through his involvement in special projects aimed at improving scientific and technological innovation capabilities. His funded studies focus on understanding the molecular mechanisms by which PD-L1 mutations influence immune escape and the efficacy of PD-1/PD-L1 inhibitors in gastric cancer. His work continues to shape the future of precision oncology, fostering new therapeutic paradigms that enhance patient survival and transform cancer treatment worldwide.

Profile: Orcid

Featured Publications

Wang, H., Yang, Y., Zhang, J., Chen, W., Dai, J., Li, C., & Li, Q. (2025). Integrating single-cell RNA sequencing and artificial intelligence for multitargeted drug design for combating resistance in liver cancer. NPJ Precision Oncology.

Che, G., Yin, J., Wang, W., Luo, Y., Chen, Y., Yu, X., Wang, H., Liu, X., Chen, Z., Wang, X., et al. (2024). Circumventing drug resistance in gastric cancer: A spatial multi-omics exploration of chemo and immuno-therapeutic response dynamics. Drug Resistance Updates, 101080.

Song, J., Zhang, J., Shi, Y., Gao, Q., Chen, H., Ding, X., Zhao, M., Zhu, C., Liang, L., Sun, X., et al. (2024). Hypoxia inhibits ferritinophagy-mediated ferroptosis in esophageal squamous cell carcinoma via the USP2-NCOA4 axis. Oncogene.

Wu, C., Zhang, G., Wang, L., Hu, J., Ju, Z., Tao, H., Li, Q., Li, J., Zhang, W., Sheng, J., et al. (2024). Spatial proteomic profiling elucidates immune determinants of neoadjuvant chemo-immunotherapy in esophageal squamous cell carcinoma. Oncogene.

Luo, H., Hu, B., Gu, X.-R., Chen, J., Fan, X.-Q., Zhang, W., Wang, R.-T., He, X.-D., Guo, W., Dai, N., et al. (2024). The miR-23a/27a/24-2 cluster drives immune evasion and resistance to PD-1/PD-L1 blockade in non-small cell lung cancer. Molecular Cancer.

Mo, Y., Han, Y., Chen, Y., Fu, C., Li, Q., Liu, Z., & Xiao, M. (2024). ZDHHC20 mediated S-palmitoylation of fatty acid synthase (FASN) promotes hepatocarcinogenesis. Molecular Cancer.